ClinicalTrials.gg

Program

osavampator

Also written as “NBI-1065845”, “TAK-653” and “Osavampator”.

Its studies are mostly in Depressive Disorder, Major · Depressive Disorder · Depressive Disorder, Treatment-Resistant, led by 2 companies.

Furthest: phase 3, since Jan 15, 20259 company-led studies, 5 open or runningNext primary completion: Jul 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurocrine Biosciences85 open or runningphase 3since Jan 15, 2025Sep 9, 2015Jul 2027phase 3 · NCT06911112
Takeda10 open or runningphase 2since Oct 13, 2017Oct 13, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2015First study: phase 1 study in Depressive DisorderNew to Neurocrine BiosciencesNeurocrine Biosciences · NCT02561156 · 88 enrolled · United Kingdom
  2. Oct 13, 2017Takeda's first study: phase 2 study in Depressive Disorder, Treatment-ResistantNew to TakedaTakeda · NCT03312894
  3. Jan 2, 2019Phase 1 study in Healthy VolunteersNeurocrine Biosciences · NCT03792672 · 24 enrolled · Netherlands
  4. Nov 18, 2021Phase 2 study in Depressive Disorder, MajorNeurocrine Biosciences · NCT05203341 · 183 enrolled · United States, Bulgaria, Czechia and more
  5. Jan 15, 2025Phase 3 study in Depressive Disorder, MajorNeurocrine Biosciences · NCT06786624 · 200 planned · United States
  6. Mar 28, 2025Phase 3 study in Depressive Disorder, MajorNeurocrine Biosciences · NCT06911112 · 200 planned · United States, Bulgaria, Lithuania and more
  7. Apr 30, 20252 phase 3 studies in Depressive Disorder, MajorNeurocrine Biosciences · NCT06966401, NCT06963021
  8. Sep 19, 2025Phase 3 study in Depressive Disorder, MajorNeurocrine Biosciences · NCT07196501 · 550 planned · United States, Australia, Bulgaria and more

Ahead

  1. Jul 2027Primary completion: phase 3 study in Depressive Disorder, MajorNeurocrine Biosciences · NCT06963021
  2. Jul 2027Primary completion: phase 3 study in Depressive Disorder, MajorNeurocrine Biosciences · NCT06911112
  3. Jul 2027Primary completion: phase 3 study in Depressive Disorder, MajorNeurocrine Biosciences · NCT06786624
  4. Jul 2028Primary completion: phase 3 study in Depressive Disorder, MajorNeurocrine Biosciences · NCT07196501

TargetBeta

“Glutamate receptor ionotropic AMPA positive allosteric modulator”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07196501Depressive Disorder, Major · United States, Australia, Bulgaria and more3RecruitingNeurocrine BiosciencesJul 2028550
NCT06966401Depressive Disorder, Major · United States, Australia, Belgium and more3RecruitingNeurocrine BiosciencesMay 2029850
NCT06963021Depressive Disorder, Major · United States, Belgium, Canada and more3RecruitingNeurocrine BiosciencesJul 2027200
NCT06911112Depressive Disorder, Major · United States, Bulgaria, Lithuania and more3RecruitingNeurocrine BiosciencesJul 2027200
NCT06786624Depressive Disorder, Major · United States3RecruitingNeurocrine BiosciencesJul 2027200
NCT05203341Depressive Disorder, Major · United States, Bulgaria, Czechia and more2CompletedNeurocrine BiosciencesJan 10, 2024183
NCT03792672Healthy Volunteers · Netherlands1CompletedNeurocrine BiosciencesMay 15, 201924
NCT03312894Depressive Disorder, Treatment-Resistant2WithdrawnTakedaFeb 28, 20190
NCT02561156Depressive Disorder · United Kingdom1CompletedNeurocrine BiosciencesSep 11, 201788

How it is read

Names in the registry

  • “NBI-1065845”, 5 entries
  • “TAK-653”, 3 entries
  • “Osavampator”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.